Pifeltro 100 mg film-coated tablets

*
Pharmacy Only: Prescription
  • Company:

    MSD Ireland (Human Health) Limited
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

Updated on 29 October 2024

File name

PIFELTRO-H-C-4747-WS-2706-030-SPC-IE-en-092024.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update of sections 4.4 and 4.8 of the SmPC to add a new warning on Severe Skin Reactions and add "toxic epidermal necrolysis (TEN)" to the list of adverse drug reactions (ADRs). Date of last renewal added and editorial changes throughout the other sections of the SPC.

Updated on 29 October 2024

File name

QRD-IE-MT-PIFELTRO-LFT-WS-2706-030.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to warnings or special precautions for use
  • Change to further information section

Free text change information supplied by the pharmaceutical company

To add a new warning on Severe Skin Reactions and add "toxic epidermal necrolysis (TEN)" to the list of possible side effects. A change to Local Representative email address for IE and removal of UK(NI) local representative details are also made.

Updated on 21 July 2023

File name

PIFELTRO-H-C-4747-R-027-SPC-IE-en-072023.pdf

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text
  • Removal of Black Inverted Triangle

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Removal of black inverted triangle. Editorial changes throughout the other sections of the SPC.

Updated on 21 July 2023

File name

QRD-IE-MT-UKNI-PIFELTRO-LFT-R-027.pdf

Reasons for updating

  • Change to section 6 - date of revision
  • Removal of Black Inverted Triangle

Updated on 20 October 2022

File name

PIFELTRO-H-C-4747-IG-1535-024-SPC-IE-en-Sept2022-CHMP-HIV-Transmission-Update.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4 – deletion of information regarding sexual transmission.

Section 4.6 – update to text regarding HIV transmission in breastfeeding.

Section 10 – The last revision date is updated.

Updated on 20 October 2022

File name

QRD-IE-MT-UKNI-PIFELTRO-LFT-IG-1535-024-CRT-FT-Sept-2022.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to other sources of information section

Free text change information supplied by the pharmaceutical company

Deletion of “Passing HIV to others” section and update to text regarding HIV transmission in breastfeeding. Change in date of last revision.

Updated on 26 August 2022

File name

PIFELTRO-H-C-4747-WS2249-022-SPC-IE-en-Jul2022 (clean).pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 5.1 - changes related to resistance in cell culture

Section 5.2 update the lay-out of the unit for AUC from μg.h/mL to μg•h/mL

Section 10 – The last revision date is updated

Updated on 26 August 2022

File name

QRD IE-MT-UKNI-PIFELTRO-LFT-WS-2249-CRT-FT Jul2022.pdf

Reasons for updating

  • Change to section 6 - what the product contains
  • Change to other sources of information section

Free text change information supplied by the pharmaceutical company

Change in formatting of marketing authorisation holder and manufacturer and change in date of last revision.

Updated on 25 August 2022

File name

QRD IE-MT-UKNI-PIFELTRO-LFT-WS-2249-CRT-FT Jul2022.pdf

Reasons for updating

  • Change to section 6 - what the product contains
  • Change to other sources of information section

Free text change information supplied by the pharmaceutical company

Change in formatting of marketing authorisation holder and manufacturer and change in date of last revision.

Updated on 28 July 2022

File name

QRD IE-MT-UKNI-PIFELTRO-LFT-BRX-NIP clean FT 16-May-2022.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to other sources of information section

Free text change information supplied by the pharmaceutical company

Addition of United Kingdom (Northern Ireland) details to section 4 and section 6 of the PIL.

Updated on 27 April 2022

File name

PIFELTRO-H-C-4747-WS2605-019-SPC-IE-en-Apr2022.pdf

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.1 & 4.2 – update relates to the addition of paediatric indication

Section 4.8 -  update relates to the paediatric population

Section 5.1 & 5.2 – changes relate to the paediatric population

Section 10 – The last revision date is updated

Updated on 27 April 2022

File name

QRD-PIFELTRO-IE-MT-WS2065-019-LFT-Apr2022.pdf

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - use in children and adolescents
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

    • Change to section 1 - what the product is used for  - changes relate to addition of paediatric indication
    • Change to section 2 - use in children and adolescents  - changes relate to addition of paediatric indication
    • Change to section 6 - date of revision - The last revision date is updated.

Updated on 27 July 2020

File name

QRD-PIFELTRO-IB008-LFT-IE-MT-EN (002).pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 27 November 2019

File name

PIFELTRO-H-C-4747-IB-008-SPC-en-CRT (002).pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to 96 weeks resistance data table + QRD version 10.1

Updated on 27 November 2019

File name

PIFELTRO-H-C-4747-IB-008-SPC-en-CRT (002).

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to 96 weeks resistance data table + QRD version 10.1

Updated on 27 September 2019

File name

PIFELTRO-H-C-4747-IB-007-SPC-en-CRT (002).pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

PRAC Autoimmune Hepatitis

Updated on 27 September 2019

File name

QRD-PIFELTRO-H-C-04747-IB-007-PI-IE-MT (002).pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Change to section 2 – What you need to know – warnings and precautions

Change to section 6 – Revision Date

Updated on 20 May 2019

File name

PIFELTRO-H-C-4747-II-003-PI-en-CRT.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 5.1 - Pharmacodynamic properties

Change to section 10 - Date of revision of the text

Addition of 96 weeks data P018 P021

Updated on 20 May 2019

File name

PIFELTRO-H-C-4747-II-003-PI-en-CRT.

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 5.1 - Pharmacodynamic properties

Change to section 10 - Date of revision of the text

Addition of 96 weeks data P018 P021

 

Updated on 10 May 2019

File name

QRD-PIFELTRO-H-C-04747-II-001-PI-IE-MT.pdf

Reasons for updating

  • Change to section 6 - date of revision

Updated on 10 May 2019

File name

PIFELTRO-H-C-04747-II-001-SPC.pdf

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 10 - Date of revision of the text

 

Updated on 29 April 2019

File name

QRD-PIFELTRO-H-C-04747-II-001-PI-IE-MT.pdf

Reasons for updating

  • New PIL for new product

Updated on 29 April 2019

File name

PIFELTRO-H-C-04747-II-001-SPC.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

New SPC for new product